Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
She developed tonic seizures and epileptic spasms at 6 months of age and was diagnosed with symptomatic West syndrome and underwent adrenocorticotropic hormone therapy but her seizures were refractory.
|
31492455 |
2020 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, relapse rates were 16% (KD) and 43% (ACTH, P = 0.09), and seizure freedom at last follow-up was 40% (KD) and 27% (ACTH, P = 0.18).
|
30801699 |
2019 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Antiepileptic drugs, namely oxcarbazepine, phenytoin, valproate, levetiracetam, and clonazepam, as well as adrenocorticotropic hormone therapy failed to reduce the severity of the seizures.
|
29625812 |
2018 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Adrenocorticotropic hormone therapy may achieve partial or complete remission of seizures, but the effect is usually temporary.
|
30194038 |
2018 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Administration of adrenocorticotropic hormone (ACTH) for seizure control was statistically significant compared to other antiepileptic drugs (p < 0.05).
|
28140735 |
2017 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Seizures were controlled in a few weeks with intramuscular synthetic ACTH, followed by valproic acid.
|
25500573 |
2015 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
To maintain efficacy, we treated two children with intractable epilepsy with weekly ACTH therapy for 1 year and described the changes in clinical seizures, electroencephalograms, developmental assessments and side effects.
|
25149137 |
2015 |
Seizures
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
ACTH therapy was introduced, resulting in a significant improvement in EEG activity and gradual reduction in seizure frequency, with cessation at age 13 weeks.[Published with video sequences].
|
23774309 |
2013 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The administration of adrenocorticotropic hormone was partially effective for stopping the condition, and the seizure type evolved into brief tonic seizures at 6 months.
|
22656320 |
2013 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Despite trials of antiepileptic drugs (mean, 5; range, 3-7), steroids/adrenocorticotropic hormone (4/6; 67%), and the ketogenic diet (6/6; 100%), all children manifested refractory seizures at last follow-up.
|
22264704 |
2012 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Adrenocorticotropic hormone (ACTH) has been used as the major therapy for infantile spasms since 1958 because it effectively suppresses seizures; it also normalizes the electroencephalogram in the short-term treatment of infantile spasms.
|
20722663 |
2010 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
ACTH completely controlled the seizures, but was halted because of the progression of ventricular hypertrophy.
|
14636357 |
2003 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
ACTH therapy resulted in prompt remission of seizures and resolution of EEG abnormalities.
|
8888053 |
1996 |
Seizures
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
The seizures occurred following the suppression of infantile spasms with adrenocorticotropic hormone therapy and disappeared following the cessation of clonazepam administration.
|
1656808 |
1991 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
The seizures occurred following the suppression of infantile spasms with adrenocorticotropic hormone therapy and disappeared following the cessation of clonazepam administration.
|
1656808 |
1991 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
The features of these are 1) late onset of seizures, 2) good response to ACTH therapy, 3) no significant abnormalities of brain except for agenesis of corpus callosum.
|
2169275 |
1990 |
Seizures
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
The features of these are 1) late onset of seizures, 2) good response to ACTH therapy, 3) no significant abnormalities of brain except for agenesis of corpus callosum.
|
2169275 |
1990 |
Seizures
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
Therefore, we considered that the new brief tonic seizures, which appeared only during sleep in the course of ACTH therapy, were ACTH-induced seizures.
|
2554740 |
1989 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Therefore, we considered that the new brief tonic seizures, which appeared only during sleep in the course of ACTH therapy, were ACTH-induced seizures.
|
2554740 |
1989 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Cardiac hypertrophy associated with ACTH therapy for childhood seizure disorder.
|
2821097 |
1987 |
Seizures
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
Cardiac hypertrophy associated with ACTH therapy for childhood seizure disorder.
|
2821097 |
1987 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
[Modalities and side effects of ACTH therapy of diffuse epilepsy in children].
|
6324019 |
1984 |
Seizures
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
[Modalities and side effects of ACTH therapy of diffuse epilepsy in children].
|
6324019 |
1984 |
Seizures
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
Lower doses of systemic morphine (50 mg/kg) were necessary to block i.c.v. morphine seizures than the dose (100 mg/kg) necessary to block seizures induced by i.c.v.Leu-enkephalin and beta-endorphin.
|
7127082 |
1982 |
Seizures
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Lower doses of systemic morphine (50 mg/kg) were necessary to block i.c.v. morphine seizures than the dose (100 mg/kg) necessary to block seizures induced by i.c.v.Leu-enkephalin and beta-endorphin.
|
7127082 |
1982 |